- Serological surveillance reveals a high exposure to SARS-1
- CoV-2 and altered immune response among COVID-19 2
- unvaccinated Cameroonian individuals 3
- Arlette Flore Moguem Soubgui<sup>1,2</sup>, Wilfred Steve Ndeme Mboussi<sup>1,2</sup>, Loick Pradel Kojom 4
- Foko<sup>2,3\*</sup>, Elisée Libert Embolo Enyegue<sup>4</sup>, Martin Luther Koanga Mogtomo<sup>1,2\*</sup> 5
- <sup>1</sup> Department of Biochemistry, Faculty of Science, The University of Douala, Cameroon 6
- 7 <sup>2</sup> Centre de Recherche et d'Expertise en Biologie, Douala, Cameroon
- 8 <sup>3</sup> Department of Animal Biology, Faculty of Science, The University of Douala, Cameroon
- <sup>4</sup> Center for Research on Health and Priority Diseases, Ministry of Scientific Research and 9
- 10 Innovation, Yaounde, Centre Region, Cameroon
- 11 Short title: SARS-CoV-2 seroprevalence and immune response in Cameroon
- \*Corresponding authors 12
- 13 koanga@yahoo.com (MLKM) and kojomloick@gmail.com (LPKF)
- 15 **ORCID Authors**

- 16 Arlette Flore Moguem Soubgui (https://orcid.org/0000-0001-8229-9533)
- 17 Loick Pradel Kojom Foko (https://orcid.org/0000-0002-4286-147X)
- Elisée Libert Embolo Enyegue (https://orcid.org/0000-0002-5802-6858) 18
- 19 Martin Luther Koanga Mogtomo (https://orcid.org/0000-0003-4323-9428) NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### Abstract

20

21

26

### Background

- 22 Surveillance of COVID-19/SARS-CoV-2 dynamics is crucial to understanding natural history
- and providing insights into the population's exposure risk and specific susceptibilities. This
- 24 study investigated the seroprevalence of SARS-CoV-2 antibodies, its predictors, and
- 25 immunological status among unvaccinated patients in Cameroon.

#### **Materials and Methods**

- 27 A multicentre cross-sectional study was conducted between January and September 2022 in
- 28 the town of Douala. Patients were consecutively recruited, and data of interest were
- 29 collected using a questionnaire. Blood samples were collected to determine Immunoglobin
- 30 titres (IgM and IgG) by ALFA, CD4+ cells by flow cytometry, and interferon gamma (IFN- γ)
- 31 and interleukin-6 (IL-6) by ELISA.

#### 32 Results

- A total of 342 patients aged 41.5 ± 13.9 years were included. Most participants (75.8%) were
- asymptomatic. The overall prevalence of IgM and IgG was 49.1% and 88.9%, respectively.
- 35 Ageusia and anosmia have displayed the highest positive predictive values (90.9% and
- 36 82.4%) and specificity (98.9% and 98.3%). The predictors of IgM seropositivity were being
- 37 aged 60 70 years (aOR = 0.54, p = 0.02) and ageusia (aOR = 9.31, p = 0.01), whereas those
- of IgG seropositivity included health facility (aOR = 0.23, p = 0.02) and ageusia (aOR = 0.21, p
- 39 = 0.04). CD4+, IFN-γ, and IL-6 were impaired in seropositive individuals, with a confounding
- 40 role of socio-demographic factors or comorbidities.

Page **3** of **38** 

**Conclusion** 

41

45

48

49

- Although the WHO declared the end of COVID-19 as a public health emergency, the findings 42
- 43 of this study indicate the need for continuous surveillance to adequately control the disease
- in Cameroon. 44

#### **Keywords**

- SARS-CoV-2; seroprevalence; predictors; immunological status; unvaccinated people; 46
- 47 Cameroon

## Introduction

- 50 A large number of pathogens have emerged and re-emerged in the last two decades and
- negatively impact the health, wellbeing, and economy of the world's populations. Several 51
- factors, greatly due to anthropic activities and climate change, have been indexed as the 52
- main causes of the appearance and/or resurgence of several infectious diseases [1]. The 53
- severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a positive sense single-54
- stranded ribonucleic acid virus, responsible for coronavirus disease 2019 (COVID-19) [2], is 55
- 56 the latest example of this catastrophic scenario of emerging pathogens. Since its initial
- emergence in Wuhan, Hubei region, China, in December 2019, an estimated ~677 million 57
- cases and ~6.9 million deaths were attributed to SARS-CoV-2 as of 10 March 2023 58
- 59 (https://coronavirus.jhu.edu/map.html).
- Methods relying on molecular detection of the viral genome, i.e., retrotranscriptase 60
- 61 quantitative polymerase chain reaction (RT-qPCR), are gold standards for diagnostic and

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

surveillance purposes. In developed areas, RT-qPCR is highly operational at the national level, but it is not the case in developing regions such as sub-Saharan Africa, where this technique is not affordable for most health facilities, especially those from remote and/or hard-to-reach population areas. In addition, RT-qPCR-based estimates do not reflect the real circulation and spread of SARS-CoV-2 in populations, as this technique can give falsenegative results especially at initial testing (i.e., at the first healthcare encounter) [3], and is commonly recommended for individuals presenting COVID-19-like respiratory signs and symptoms [4]. In this context, it is crucial to develop alternative methods to overcome these main limitations of molecular techniques. Serological testing for SARS-CoV-2 infection has become an important pillar in surveillance efforts. Seroprevalence studies quantify the number of individuals who have developed an immune response, i.e. antibodies, against a pathogen. The studies rely of the detection of immunoglobulins (e.g., IgG, IgM) produced followed infection with SARS-CoV-2. The production of these anti-SARS-CoV-2 antibodies corresponds to several phases of the natural course of viral infection. IgM are produced early in the humoral immune response against SARS-CoV-2 infection, and then they are switched to IgG, which has a higher affinity for viral antigens than IgM [5,6]. Not only can the large scale implementation of highly sensitive and specific serological tests help to know the real picture of spread of SARS-CoV-2 by tracking asymptomatic carriers of the virus who are missed by traditional surveillance systems, but these can also evaluate the effectiveness of control measures [5]. There is a lack of serological studies in African settings in the context of boosting efforts to continuous surveillance and control the disease. We therefore conducted a serological study to determine the prevalence and determinants of anti- SARS-CoV-2 antibodies among

Page **5** of **38** 

unvaccinated individuals living in the town of Douala, Cameroon. In addition, we evaluated

variations in markers of immune responses (interferon, lymphocytes, and interleukins).

#### **Materials and Methods**

### Study design

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

This cross-sectional study was conducted between January, 1st and September, 31st, 2022 in seven health facilities in the town of Douala, Littoral Region, Cameroon. The study sites included Bangue district hospital, Boko health care centre, Bonassama district hospital, Cité des Palmiers district hospital, Deido district hospital, New Bell district hospital, and Nylon district hospital. Douala is the economic capital and most populated town of Cameroon. Populations living in this town are highly diverse, with the predominance of three ethnic groups (Duala, Bamileke, and Bassa) [7]. A questionnaire was administered to each participant to collect sociodemographic, anthropometric, and clinical information, while blood samples were collected to measure immune response parameters, respectively. A summary of the main activities conducted during the study is summarized in Fig 1.

Fig 1. Flow diagram of the study. COVID-19: Coronavirus disease 2019, Ig: Immunoglobulin,

CD: Cluster of differentiation, IFN-y: Interferon gamma, IL-6: Interleukin 6

## **Eligibility criteria**

We included all Cameroonian patients of both sexes, aged > 18 years old, settled in Douala, and having signed an informed consent form. In contrast, we excluded from this study: i)

foreigners, ii) patients who were not willing to participate, iii) those who refused to sign an informed consent form, iv) those admitted to intensive care units; and v) those for whom blood collection was impossible.

## Sample size calculation

Participants were recruited consecutively using random sampling to limit selection and information biases. The sample size was determined using Lorentz's formula  $n = [Z^2 \times p \times (1 - p)]/d^2$ , where n = the required sample size, Z = statistics for the desired confidence interval (Z = 1.96 for 95% confidence level), d = accepted margin of error (d = 5%), and p = seroprevalence of SARS-CoV-2 antibodies in Africa (19.5%) [8]. The required sample size for this study was estimated as n = 241 participants.

### **Data collection**

About three millilitres of whole blood were collected from each patient by venepuncture in properly labelled tubes. A structured pre-tested questionnaire was used to collect data of interest, which consisted of sociodemographic information (age, gender, educational level, occupation, and marital status), anthropometric parameters (weight, height, body mass index), and clinical information (clinical signs and symptoms, COVID-19 vaccination uptake, and presence of comorbidities such as diabetes and hypertension).

## **Determination of immune response parameters**

Venous blood samples were used to determine levels of CD4+, immunoglobulins M and G (IgM and IgG), interferon gamma (IFN-γ) and interleukin 6 (IL-6). The blood level of CD4+ was determined using a Sysmex XF-1600™ Flow Cytometer (https://www.sysmex-ap.com). Blood

samples were centrifuged, and the resulting supernatant (serum) was used to determine levels of immunoglobulins, IFN-γ, and IL-6. All serum samples were tested for anti-SARS-CoV-2 virus IgG and IgM antibodies using a VIDAS® SARS-COV-2 IgG/IgM kit (Reference 423833) (www.biomerieux-usa.com) which is an automated assay based on the enzyme-linked immunofluorescent assay (ALFA) technique. Samples were considered positive for both IgG and IgM when the test values were greater than 1. IFN-γ and IL-6 were measured by sandwich enzyme-linked immunosorbent assay (ELISA). Spectrophotometric measurements of IFN-γ and IL-6 were done at wavelength 450 nm. All experiments were performed in duplicate and in accordance with the manufacturer's instructions.

#### **Ethical statements**

An ethical authorization was issued by the institutional review board of the University of Douala (N° 2945 CEI-UDo/12/2021/T), Littoral Health Regional Delegation (N° 0038/AAR/MINSANTE/DRSPL/BCASS), and Douala Laquintinie Hospital (N° 08179/AR/MINSANTE/DHL) (S1 Fig). The study was explained to participants in the two official languages they understood best (French or English), and their questions were answered. Patients were informed about the objectives, advantages, and risks of the study, and then asked to sign a written informed consent form before their enrolment. Participants were informed that the study was strictly voluntary, and they were free to decline answering any question or totally withdraw if they so wished at any time.

## Statistical analysis

Data were presented as percentages with 95% confidence intervals (95%CI) for categorical variables, and mean ± standard deviation (SD) or standard error (SE) for continuous

variables. The percentages were compared using Fisher's exact and Pearson's independence chi-square  $(\chi^2)$  tests. Continuous variables were tested for normal distribution using the Kolmogorov-Smirnov test to decide whether parametric and non-parametric statistical tests were suitable for comparative analyses (S2 Fig). Parametric tests including one-way analysis of variance (ANOVA), post-hoc Duncan's test, unpaired samples Student t-test and Pearson correlation were used for variables following a Gaussian distribution. The non-parametric versions of these tests (i.e., Kruskal-Wallis test, Mann-Whitney test and Spearman correlation) were used for variables that failed to reach a Gaussian distribution. Univariate and multivariate logit models were used to identify determinants of SARS-CoV-2 antibodies. The association between independent variables and SARS-CoV-2 antibodies was quantified by crude and adjusted odds ratios (cOR and aOR), 95%CIs, and level of statistical significance. The independent variables included in the logit model were health facility, gender, age, marital status, educational level, occupation, comorbidities, clinical signs and symptoms, blood group, COVID-19 vaccination uptake, history of past COVID-19, and history of recent infection). Based on the findings of the univariate analysis, variables that were significant in the univariate analysis were used to build the multivariate logistic model. A two-tailed pvalue < 0.05 was considered statistically significant. No imputation was performed for missing values. GraphPad version 5.03 for Windows (GraphPad PRISM, San Diego, Inc., California, USA), SPSS version 16 for Windows (SPSS IBM, Inc., Chicago, Illinois, USA), and StatView version 5.0 for Windows (SAS Institute, Chicago, Illinois, USA) software were used to perform statistical analyses. All analyses were performed as recommended in the SAMPL Guidelines [9].

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

### Results

#### SARS-CoV-2 antibody response by COVID-19 status

Unvaccinated patients accounted for 81.4% of the patients (Fig 2a). The serum titres of IgM were significantly higher in unvaccinated patients compared to fully vaccinated patients (p = 0.03) (Fig 2b), but no significant difference was found for IgG (Fig 2c). Unvaccinated patients were analysed in the next sections as per the study objectives.

Fig 2. Proportion of unvaccinated patients (a), and serum levels of IgM (b) and IgG (c) by COVID-19 vaccination status. The one-way analysis of variance (ANOVA) and Duncan's post-hoc tests were used to make pairwise comparisons between groups. In Figures 2 b and 2c, only statistically significant comparisons were showed on the graphs. \*Statistically significant at p-value < 0.05

## Characteristics of the unvaccinated participants

Of the 342 participants, females and elderly people accounted for 47.7% and 13.2%, respectively. The mean age  $\pm$  SD of the study population was 41.5  $\pm$  13.9 years. Obesity was the main comorbidity (24.6%) found in participants. The bulk of participants (75.8%) were asymptomatic, even though a few individuals presented clinical symptoms represented mainly by cough (12.1%), severe fatigue (10.9%), and headache (9%) (Table 1).

Page **10** of **38** 

### Table 1. Details of the patients included in the study.

Variables	n (%)
Sociodemographic data (N = 342)	
Females, n (%)	163 (47.7%)
Age ≥ 60 years, <i>n</i> (%)	45 (13.2%)
Mean age ± SD (years)	41.5 ± 13.9
Married, n (%)	179 (52.3%)
University level, n (%)	208 (60.8%)
Comorbidities (N = 342)	
Obesity, <i>n</i> (%)	84 (24.6%)
Hypertension, n (%)	37 (10.8%)
Diabetes, n (%)	21 (6.1%)
Asthma, <i>n</i> (%)	11 (3.2%)
Heart failure, n (%)	8 (2.3%)
Human immunodeficiency infection, n (%)	5 (1.5%)
Cancer, <i>n</i> (%)	2 (0.6%)
Stroke, <i>n</i> (%)	2 (0.6%)
Coronary heart disease, n (%)	1 (0.3%)
Renal impairment, <i>n</i> (%)	0 (0.0%)
Clinical signs/symptoms (N = 342)	
Asymptomatic, n (%)	258 (75.8%)
Cough, <i>n</i> (%)	49 (14.3%)
Severe fatigue, n (%)	40 (11.7%)

Page **11** of **38** 

Headache, n (%)	35 (10.2%)
Fever, n (%)	32 (9.4%)
Respiratory difficulties, n (%)	27 (7.9%)
Sore throat, n (%)	27 (7.9%)
Running nose, n (%)	23 (6.7%)
Ageusia, n (%)	22 (6.4%)
Anosmia, n (%)	17 (4.9%)
Irritability/Confusion, n (%)	9 (2.6%)
Loss of appetite, n (%)	5 (1.5%)
Nausea, <i>n</i> (%)	4 (1.2%)
Diarrhoea, n (%)	4 (1.2%)
Vomiting, n (%)	2 (0.6%)

## Overall prevalence of SARS-CoV-2 antibodies among COVID-19

## unvaccinated patients

194

195

196

197

198

199

200

201

202

A high proportion of patients were positive for both anti-SARS-CoV-2 antibodies, with an overall prevalence of 49.1% (n = 168, 95%Cl 43.9 – 54.4%) for IgM, and 88.9% (n = 304,95%CI 85.1 – 91.8%) for IgG. By combining the two antibodies, the prevalence was 96.8% (n = 331, 95%CI 94.3 – 98.2%). A statistically significant geographical variation in the prevalence of IgG, with the highest prevalence rate in patients from the Boko hospital (100%) and the lowest rate in patients from the Deido hospital (63.6%) (Fig 3 and S3 Table). No significant

Page 12 of 38

difference was found between the prevalence of IgM (p = 0.51) or Ig G + IgM (p = 0.22) after stratification by geographical area (Fig 3 and S3 Table).

Fig 3. Prevalence of SARS–CoV–2 antibodies by study sites. The map was generated using AcgGIS v8.1 software (Esri, Redlands, CA, USA) and GraphPad version 5.03 for Windows (GraphPad PRISM, San Diego, Inc., California, USA). The pie charts depict the prevalence of patients positive for IgM (black section), IgG (pink section) and IgG + IgM (purple section). \*For Deido district hospital, the sample collection site was located in Bonamoussadi neighbourhood. \*\* For Bangue district hospital, the sample collection site was located in Akwa neighbourhood

#### Seroprevalence profile by clinical status among COVID-19

## unvaccinated patients

The prevalence of IgG and/or IgM by clinical symptoms is depicted in Figure 4. Overall, the presence of IgM was more frequently seen among symptomatic patients. The trend was inverted regarding IgG antibodies, but there was no statistically significant difference for the concomitant presence of IgM + IgG. For instance, higher proportions of IgM+ patients were found in those with fever (71.9% vs 46.8%, p = 0.0008), ageusia (90.9% vs 46.3%, p < 0.0001), and anosmia (82.4% vs 47.4%, p = 0.005) (Fig 4 and S4 Table). Moreover, ageusia and anosmia were the COVID-19 symptoms that displayed the highest positive predictive values (90.9% and 82.4%) and specificity (98.9% and 98.3%) (S5 Table).

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

Fig 4. Prevalence of SARS-CoV-2 antibodies by main clinical symptoms. Ig: Immunoglobulin, n.s: Not significant, SARS–CoV–2: Severe acute respiratory syndrome coronavirus 2. Each bar represents the proportion of patients seropositive with respect to clinical symptoms. Only symptoms with occurrence > 15 were included in the analysis. Pearson's independence chi-square and Fisher's exact tests were used to compare percentages. \*Statistically significant at \*p-value < 0.05, \*\*p-value < 0.01, and \*\*\* p-value < 0.0001 Seroprevalence by demographical information and comorbidities among COVID-19 unvaccinated patients The variation of seroprevalence by demographical details and comorbidities is summarized in S6 Table. The prevalence of IgM was significantly higher in patients aged below 30 years (59.8%) and then decreased, with the lowest rates seen in patients 70 years (27.3%). The proportion of patients with IgG antibodies was higher in non-asthmatic patients as compared to their asthmatic counterparts (89.7% vs 63.6%, p = 0.02). No significant association was found between the presence of IgM and IgG antibodies, demographical characteristics, or comorbidities (S6 Table). Determinants of SARS-CoV-2 antibody response among COVID-19 unvaccinated patients Based on univariate logistic regression analysis, a total of four factors associated with the presence of IgM antibodies were identified: age, marital status, frequent healthcare seeking,

and occupation. The risk of the presence of IgM was reduced by 63% in patients aged 60-70 years (cOR = 0.37, 95%CI 0.16-0.84, p=0.01) compared to those aged < 30 years. Similarly, the risk of IgM was reduced by 75% (cOR = 0.25, 95%CI 0.07-0.94, p=0.04) in divorced or widowed patients, and by 51% (cOR = 0.49, 95%CI 0.25-0.98, p=0.04) in patients working in the formal sector compared to singles and students, respectively. In contrast, the odds of being positive for IgM were nearly two-fold higher in frequently seeking care individuals (cOR = 1.71, 95%CI 1.09-2.66, p=0.01) (Table 2). Regarding IgG, two factors were identified namely health facility and asthma. The risk of being positive for IgG was reduced in patients from the Deido hospital (cOR = 0.16, 95%CI 0.05-0.48, p=0.002) compared to those recruited at the Bangue hospital. Likewise, the odds of being positive for IgG were reduced in asthmatic patients (cOR = 0.20, 95%CI 0.06-0.72, p=0.01).

Table 2. Univariate logistic regression between SARS-CoV-2 antibodies, demographical information, clinical data and comorbidities among COVID-19 unvaccinated patients.

		IgM		IgG	
Variables	Categories	cOR (95%CI)	р	cOR (95%CI)	р
Sociodemographic o	characteristics				
Health facility	Bangue	1		1	
	Boko	0.73 (0.27 - 1.95)	0.53	0.71 (0.15 - 2.58)	0.97
	Bonassama	1.38 (0.73 - 2.60)	0.31	0.85 (0.29 - 2.51)	0.76
	Cité des Palmiers	1.10 (0.59 - 2.05)	0.76	0.73 (0.26 - 2.06)	0.55
	Deido	0.83 (0.33 - 2.09)	0.69	0.16 (0.05 - 0.48)	0.001*
	New-Bell	0.69 (0.33 - 1.46)	0.34	1.09 (0.28 - 4.26)	0.96
	Nylon	0.61 (0.26 - 1.41)	0.25	0.44 (0.13 - 1.42)	0.17

Page **15** of **38** 

Age (years old)	< 30	1		1	
Age (years old)	< 30			1	
	[30 - 40[	0.57 (0.31 - 1.04)	0.06	1.39 (0.56 - 3.47)	0.47
	[40 - 50[	0.59 (0.31 - 1.15)	0.06	1.83 (0.60 - 5.56)	0.28
	[50 - 60[	0.82 (0.41 - 1.66)	0.58	1.43 (0.46 - 4.37)	0.53
	[60 - 70[	0.37 (0.16 - 0.84)	0.01*	0.90 (0.29 - 2.82)	0.85
	70+	0.25 (0.06 - 1.02)	0.05	0.70 (0.13 - 3.66)	0.66
Gender	Females	1		1	
	Males	0.76 (0.49 - 1.16)	0.19	0.69 (0.35 - 1.37)	0.28
Marital status	Single	1		1	
	Married	0.72 (0.46 - 1.11)	0.12	0.54 (0.26 - 1.11)	0.09
	Divorced/Widow	0.25 (0.07 - 0.94)	0.04*	1.04 (0.12 - 8.73)	0.96
Educational level	None/Primary	1		1	
	Secondary	0.93 (0.37 - 2.32)	0.88	0.83 (0.17 - 4.01)	0.82
	University	0.98 (0.41 - 2.36)	0.97	0.77 (0.17 - 3.49)	0.73
Occupation	Student	1		1	
	Formal sector	0.49 (0.25 - 0.98)	0.04*	0.63 (0.18 - 2.17)	0.45
	Informal sector	0.59 (0.27 - 1.31)	0.19	0.53 (0.13 - 2.07)	0.35
Clinical characteristics		1			
Obesity	No	1		1	
	Yes	0.72 (0.44 - 1.18)	0.19	0.90 (0.42 - 1.94)	0.78
Diabetes	No	1		1	
	Yes	0.49 (0.19 - 1.26)	0.14	0.73 (0.21 - 2.62)	0.63
Hypertension	No	1		1	
		1		l .	1

Page 16 of 38

	Yes	0.87 (0.44 - 1.72)	0.68	0.61 (0.23 - 1.56)	0.29
Heart failure	No	1		1	
	Yes	0.34 (0.07 - 1.69)	0.19	-	-
HIV	No	1		1	
	Yes	0.69 (0.11 - 4.16)	0.68	0.49 (0.05 - 4.53)	0.53
Asthma	No	1		1	
	Yes	1.85 (0.53 - 6.43)	0.33	0.20 (0.06 - 0.72)	0.01*
History of COVID-19	No	1		1	
	Yes	0.79 (0.41 - 1.52)	0.48	5.61 (0.75 - 42.01)	0.09
Blood group	A	1		1	
	AB	0.82 (0.28 - 2.45)	0.72	1.04 (0.12 - 9.28)	0.97
	В	0.63 (0.33 - 1.22)	0.17	1.07 (0.29 - 3.98)	0.91
	0	0.98 (0.58 - 1.63)	0.93	0.41 (0.16 - 1.04)	0.06
Frequently care seeking	No	1		1	
	Yes	1.71 (1.09 - 2.66)	0.01*	0.79 (0.39 - 1.59)	0.51

- 259 95%CI: Confidence interval at 95%, COVID-19: Coronavirus disease 2019, cOR: Crude odds ratio, aOR:
- 260 Adjusted odds ratio, HIV: Human immunodeficiency virus infection, Ig: Immunoglobulin, SARS-CoV-
- 261 2: Severe acute respiratory syndrome coronavirus 2
- Univariate logistic regression analysis was performed to quantify the association between presence 262
- 263 of anti-SARS-CoV-2 antibodies (IgG and IgM), demographical information, clinical data and
- 264 comorbidities
- 265 \*Statistically significant at *p*-value < 0.05

perpetuity.

It is made available under a CC-BY 4.0 International license .

Page **17** of **38** 

It was noted that the risk of being positive for IgM was increased but decreased for IgG in 267 symptomatic patients, especially for those with fever, pain, respiratory difficulties, 268 headache, severe fatigue, ageusia, or anosmia (Table 3). For instance, the IgM-related risk 269 was increased in patients with fever (cOR = 2.91, 95%CI 1.30 - 6.49, p = 0.009), ageusia (cOR 270 271 = 11.62, 95%CI 2.67 - 50.56, p = 0.0001), and anosmia (cOR = 5.18, 95%CI 1.46 - 18.38, p = 0.01). Conversely, the risk of being positive for IgG was reduced by 85% (cOR = 0.15, 95%CI 272 0.07 - 0.35, p < 0.0001), 88% (cOR = 0.12, 95%CI 0.05 - 0.29, p < 0.0001), and 85% (cOR = 273 0.15, 95%CI 0.05 - 0.42, p = 0.0003) in patients with fever, ageusia, and anosmia, 274 275 respectively (Table 3).

# Table 3. Univariate logistic regression analysis between presence of anti-SARS-CoV-2 antibodies and clinical signs/symptoms among COVID-19 unvaccinated patients.

276

		IgM		IgG	
Variables	Categories	cOR (95%CI)	р	cOR (95%CI)	р
Cough	No	1		1	
	Yes	1.61 (0.87 - 2.97)	0.13	0.17 (0.08 - 0.35)	< 0.0001*
Fever	No	1		1	
	Yes	2.91 (1.30 - 6.49)	0.009*	0.15 (0.07 - 0.35)	< 0.0001*
Sore throat	No	1		1	
	Yes	1.85 (0.82 - 4.16)	0.14	0.51 (0.18 - 1.45)	0.21
Pain	No	1		1	
	Yes	2.86 (1.16 - 7.05)	0.02*	0.22 (0.09 - 0.56)	0.001*
Running nose	No	1		1	
	Yes	2.51 (1.01 - 6.27)	0.04*	0.25 (0.09 - 0.64)	0.004*

Page 18 of 38

Respiratory difficulties	No	1		1	
	Yes	2.65 (1.13 - 6.22)	0.02*	0.31 (0.12 - 0.80)	0.01*
Diarrhea	No	1		1	
	Yes	1.04 (0.14 - 7.44)	0.97	0.37 (0.04 - 3.64)	0.39
Headache	No	1		1	
	Yes	3.36 (1.52 - 7.40)	0.002*	0.45 (0.18 - 1.11)	0.08
Severe fatigue	No	1		1	
	Yes	3.09 (1.49 - 6.42)	0.002*	0.19 (0.09 - 0.41)	< 0.0001*
Irritability/Confusion	No	1		1	
	Yes	2.11 (0.52 - 8.58)	0.29	0.23 (0.06 - 0.98)	0.04*
Ageusia	No	1		1	
	Yes	11.62 (2.67 - 50.56)	0.001*	0.12 (0.05 - 0.29)	< 0.0001*
Anosmia	No	1		1	
	Yes	5.18 (1.46 - 18.38)	0.01*	0.15 (0.05 - 0.42)	0.0003*
Loss of appetite	No	1		1	
	Yes	-	-	0.08 (0.01 - 0.48)	0.005*

- 278 95%CI: Confidence interval at 95%, cOR: Crude odds ratio, aOR: Adjusted odds ratio, Ig:
- 279 Immunoglobulin, SARS–CoV–2: Severe acute respiratory syndrome coronavirus 2
- 280 Univariate logistic regression analysis was performed to quantify the association between presence
- 281 of anti-SARS-CoV-2 antibodies (IgG and IgM) and clinical signs/symptoms
- 282 \*Statistically significant at *p*-value < 0.05

## Predictors of anti-SARS-CoV-2 antibody response among

## unvaccinated patients

285

286

287

288

289

290

291

292

293

The predictors of the presence of IgM antibodies included age and ageusia, while health facilities and ageusia were predictors of the presence of IgG antibodies (Table 4 and S7 Table). The risk of being positive for IgM was reduced by 46% in patients aged 60 - 70 years (aOR = 0.54, 95%CI 0.18 - 0.87, p = 0.02). In contrast, the odds of IgM seropositivity were increased in patients diagnosed with ageusia (aOR = 9.31, 95%CI 1.49 - 58.08, p = 0.01).

# Table 4. Predictors of the presence of anti-SARS-CoV-2 antibodies among COVID-19 unvaccinated patients.

	IgM		IgG	
Predictors	aOR (95%CI)	p	aOR (95%CI)	p
Health facility, Deido	-	-	0.23 (0.06 - 0.83)	0.02*
Aged 60 - 70 years	0.54 (0.18 - 0.87)	0.02*	-	-
Ageusia	9.31 (1.49 - 58.08)	0.01*	0.21 (0.04 - 0.98)	0.04*

95%CI: Confidence interval at 95%, COVID-19: Coronavirus disease 2019, aOR: Adjusted odds ratio,

aOR: Adjusted odds ratio, Ig: Immunoglobulin

Multivariate logistic regression analysis was performed to identify the predictors of the presence of

anti-SARS-CoV-2 antibodies (IgG and IgM)

\*Statistically significant at p-value < 0.05

294

295

296

297

298

## Variation of the SARS-CoV-2 immune response among

#### unvaccinated patients

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

The variations in mean levels of CD4+ cells, IFN-y, and IL-6 by seropositivity status are depicted in Figure 5. No significant variation was noted for CD4+ between IgM+ patients and IgM- patients (p = 0.11). In contrast, increased levels have been observed in IFN-y (p = 0.01) and IL-6 (p = 0.04) in IgM+ patients compared to their IgM- counterparts. Regarding IgG status, the levels of CD4+ cells were significantly higher in IgG+ patients (p = 0.0048), but an inverted relation was found for IL-6 (p = 0.0001). The levels of IFN- $\gamma$  were similar between IgG+ patients and IgG- patients (p = 0.87) (Fig 5). The impact of patients' characteristics (i.e., sociodemographic, anthropometric, and clinical information) on the relation between seropositivity status, and CD4+ cells, IFN-y, or IL-6 was analysed (Fig 6). For instance, we compared the mean values of CD4+ cells, IFN-y, and IL-6 of IgM+ females with those of IgM- females, and the same comparisons were done for males. Overall, the relationship between CD4+ cells and IgM or IgG status was not influenced by patients' characteristics, with the exception of symptomatology and diabetes. The mean levels of CD4+ were significantly reduced in IgM+ symptomatic patients compared to IgMsymptomatic patients (p = 0.01), but the difference was no longer significant between IgM+ asymptomatic patients and IgM- asymptomatic patients (p = 0.16). Likewise, the same pattern was noted upon stratification of the patients by diabetic status, with a significant difference in CD4+ cells in diabetic patients (p = 0.01) but no longer in non-diabetic patients (p = 0.20). CD4+ cells were significantly higher in IgM+ non-diabetic compared to IgM+ nondiabetic (p = 0.005), but not in diabetic patients (p = 0.56). The association between seropositivity status and IFN-y or IL-6 was also modified by the patient's details (Fig 6).

Fig 5. Overall variation of CD4+ (a, d), IFN- $\gamma$  (b, e) and IL-6 (c, f) with respect to presence of anti-SARS-CoV-2 IgM and IgG antibodies. Ig: Immunoglobulin, IL-6: Interleukin 6, IFN- $\gamma$ : Interferon gamma, CD: Cluster of differentiation. The parametric unpaired sample Student's t-test, and non-parametric Mann-Whitney test ere used to compare the groups. \*Statistically significant at p-value < 0.05

Fig 6. Variation of CD4+, INF- $\gamma$  and IL-6 by seropositivity status, demographic, clinical, and comorbidity information. Ig: Immunoglobulin, SARS—CoV—2: Severe acute respiratory syndrome coronavirus 2, IL-6: Interleukin 6, IFN- $\gamma$ : Interferon gamma, CD: Cluster of differentiation. The number of participants in each group are presented in round brackets. The non-parametric unpaired sample Student's t-test was used to compare the groups. \*Statistically significant at p-value < 0.05

### **Discussion**

The epidemiological situation of SARS—CoV—2 infection is still elusive in Cameroon, and this is mainly due to a lack of testing campaigns in community. Molecular methods are the gold standard for SARS—CoV—2 testing in populations. In developing countries, their implementation at a large scale is strongly hindered by the high cost of these methods, which are limited to a few research institutes and health facilities for research and small-scale diagnosis purposes. Antibody-based assays constitute an interesting alternative to molecular methods, especially for the rapid determination of the circulation of SARS—CoV—2. This study aimed at determining the seroprevalence and determinants of SARS—CoV—2 antibodies among patients attending major health facilities for the management of COVID—19 in Douala, Cameroon.

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

The overall seroprevalence of SARS-CoV-2 was 96.9%, which is consistent with those reported in other settings such as Chile (97.3%) [10]. In contrast, lower seroprevalence values were recently reported in Portugal (2.7 – 3.9%), Mozambique (3%), Bosnia and Herzegovina (3.77%), Japan (3.9%), Denmark (5.3%), Chile (7.2%), Spain (9.6 - 21.9%), Italia (11%), Sweden (11.8%), Iran (14%), Pakistan (16%), Iran (17.1%), Iraq (23.72%), Poland (42.7%), USA (5.6 – 57.7%), and Lebanon (58.9%) [4,11,20–27,12–19]. Differences in study period, SARS-CoV-2 variants, age groups, and COVID-19 vaccine coverage could explain discrepancies between seroprevalence estimates. Also, we found higher seroprevalence against IgM compared to IgG. This is not in line with reports from Iraq, where authors found higher seroprevalence against IgG [4]. We noted that a high proportion of seropositive patients were asymptomatic, and this could indicate that patients could control the SARS-CoV-2 infection. A study found cross-reactive antibodies to SARS-CoV-2 were in circulation among HIV patients before the COVID-19 pandemics [28], thereby suggesting the presence of pre-existing anti-SARS-CoV-2- immunity that could contribute to attenuating disease severity. The presence of IgM antibodies to SARS-CoV-2 is a good proxy for recent infection, as they are produced early in the antiviral humoral immune response. Nearly half of unvaccinated patients were IgM positive, thereby suggesting a high circulation of SARS-CoV-2 among the patients, and a need for adequate control measures, especially for those manifesting COVID-19-related symptoms. This is the first seroprevalence study to report SARS-CoV-2 risk in adults in Douala, the main populous and heterogeneous town of Cameroon. Before our study, IgM seroprevalence estimates were available from studies conducted among health care workers and the general population in the town of Yaoundé [29–31].

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

The prevalence of IgG was 88.9% in this study. Such a high prevalence estimate was also reported in Cameroon by Ndongo Ateba et al. in Yaounde (18.6% to 51.3%) [32], Mansuy et al. in pregnant women from Yaoundé (77%) [33], Njuwa Fai et al. in a community-based study from Yaoundé (24%) [31], Deutou Wondeu et al. among university staff and students (71.3%) in Bandjoun, a kingdom in the West Region of Cameroon [34], Sandie et al. among blood donors from Douala and Yaoundé (66.3% to 98.4%) [35], and Diallo et al. among unvaccinated individuals (74.8%) after the Omicron wave [36]. Lower values were reported among dental teams in Germany (5.2%) [37] and young adults in Sweden (22.4%) [25]. The chances of detecting anti-SARS-CoV-2 IgG were decreased by 77% in patients attending the Deido district hospital compared to those attending the Bangue district hospital. This finding could be explained by geographical differences in the risk of infection, which have also been reported in previous studies [11]. Patients aged 60 – 70 years were less at risk of IgM seropositivity, which is consistent with earlier studies [14,19,22,36,38,39]. In Bosnia and Herzegovina, Prguda-Mujic and colleagues reported a reduced risk of positive anti-SARS CoV-2 Ig levels in patients aged over 50 years old [19]. Other studies reported a reduced risk of SARS-CoV-2 positivity in younger individuals [21,40]. This could be due to the fact that elderly individuals are more aware of risks of COVID-19, and thus preventive methods could be more effectively implemented in them [41]. This fact could also explain the reduced risk of anti-SARS CoV-2 IgG levels among asthmatic patients found in the present study. In this study, clinical symptoms were significantly associated with a higher risk of IgM seropositivity, especially anosmia and ageusia. In addition, ageusia was the strongest predictor of IgM seropositivity among the patients. Several studies across COVID-19 burden

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

varying settings also reported the clinical utility of COVID-19 evocating clinical symptoms, or more specifically, fever, anosmia, and ageusia [20,22,23,25,26,40,42]. Ferreira et al. recently reported that anosmia/dysgeusia was the most clinically discriminant symptoms in Portuguese municipal workers, with a PPV and specificity of 52.2% and 99.3%, respectively. Likewise, we found high estimates for anosmia (PPV = 82.4%, Sp = 98.3%) and for ageusia (PPV = 90.9%, Sp = 98.9%) in this study. The pathophysiological mechanism of anosmia and ageusia in COVID-19 is not yet fully understood, but studies have outlined that SARS-CoV-2 could elicit these olfactory and gustatory dysregulations either directly by infecting central nervous system and gustatory/olfactory epithelium cells, or indirectly through the production of cytokines such as tumour necrosis factor that may provoke the apoptosis of nervous cells [43,44]. In line with previous studies, the levels of IFN-y and CD4+ cells were decreased in seropositive patients. Several studies outlined a delayed, decreased, or inhibited IFN-ymediated immune response in SARS-CoV-2 and other related coronaviruses (e.g., SARS-CoV-1). This dysregulation of the IFN-γ-mediated immune response is positively correlated with the severity of COVID-19 [45,46]. The pathophysiological mechanism through which SARS—CoV—2 provokes a dysregulation of the IFN-y-mediated immune response included a production of antagonists that act by downregulating signalling pathways and/or inhibiting transcription factors [45,46]. Regarding CD4+ lymphocytes, they play a crucial role in the immune response against SARS-CoV-2 [47-49]. COVID-19 patients generally present a lymphopenia. Some authors suggested that the surveillance of lymphocyte subsets could be helpful for improved diagnosis and treatment of COVID-19 patients [50]. To be noted, the association between antibody seropositivity and CD4+, IFN-y or IL-6 was modulated by patients' characteristics. Such modulating impact have been previously reported for immune response immune in India [51], and haematological biomarkers of COVID-19 in Cameroon and India [52,53]. This is not surprising as these characteristics are well known to be predictors of SARS-CoV-2 infection, severity, or deaths [54–56]. The findings from the present study should be interpreted in light of its limitations. First, the study was conducted in seven health facilities in the town of Douala, thereby limiting its generalisability at national level. Second, the study did not capture all environmental, behavioural, and socio-demographic characteristics of patients (e.g., size of household, socio-economic status) that could have impacted the risk of SARS-CoV-2 seropositivity [21,23,42,57–59]. Third, the small number of patients with comorbidities such as heart failure limited stratification analyses to identify possible confounding variables. Finally, the antigens in the ELISA kits used were designed to target the original SARS-CoV-2 lineage that emerged in China. Several variants of the virus, such as the Omicron or delta lineages, have been reported in Cameroon during pandemic waves [60–62], and thus, it is likely that a few infection cases were missed as these antigens may not optimally detect antibodies against SARS-CoV-2 variants and that the seroprevalence is underestimated.

### **Conclusions**

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

In this study, we aimed at determining seroprevalence, determinants of SARS-CoV-2 infection, and immunological alterations among unvaccinated patients living in Douala, Cameroon. The findings indicate a high circulation of the virus among participants, with several predictors of seropositivity including advanced age, health facility, and ageusia. In general, immune response effectors (CD4+, IFN-γ, and IL-6) analysed in the study were altered in seropositive individuals, with a confounding role of socio-demographic factors or comorbidities. Although the WHO recently declared the end of COVID-19 as a global health

emergency, the findings of the present study indicate the need for continuous surveillance to adequately control the disease in Cameroon.

## **Abbreviations**

95%CI: Confidence interval at 95%, ALFA: Enzyme-linked immunofluorescent assay, ANOVA: Analysis of variance, aOR: Adjusted odds ratio, cOR: Crude odds ratio, aRR: Adjusted risk ratio, BMI: Body mass index, CD: Cluster of differentiation, cRR: Crude risk ratio, COVID—19: Coronavirus disease 2019, df: Degree of freedom, ELISA: Enzyme-linked immunosorbent assay, IFN: Interferon, Ig: Immunoglobulin, HIV: Human immunodeficiency virus, PPV: Positive predictive value, ROC: Receiver operating curve, RT-qPCR: Retrotranscriptase quantitative polymerase chain reaction, SARS—CoV—2: Severe acute respiratory syndrome coronavirus 2, SD: Standard deviation, SE: Standard error, Sp: Specificity

## **Acknowledgments**

The authors are grateful to patients having accepted to participate in the study. We also acknowledge support and technical assistance of managing authorities, medical doctors and staff of health facilities. We also acknowledge the assistance of Mr. Stephane Koum (Department of Earth Sciences, The University of Douala, Cameroon) for generating maps.

## **Author Contributions**

- **Conceptualization**: Arlette Flore Moguem Soubgui, Martin Luther Koanga Mogtomo.
- **Data curation**: Arlette Flore Moguem Soubgui, Wilfred Steve Ndeme Mboussi, Loick Pradel
- 460 Kojom Foko, Elisee Libert Embolo Enyegue.

perpetuity.

It is made available under a CC-BY 4.0 International license .

Page **27** of **38** 

461 Formal analysis: Arlette Flore Moguem Soubgui, Loick Pradel Kojom Foko, Martin Luther 462 Koanga Mogtomo. Investigation: Arlette Flore Moguem Soubgui, Wilfred Steve Ndeme Mboussi, Elisee Libert 463 464 Embolo Enyegue, Martin Luther Koanga Mogtomo. 465 Methodology: Arlette Flore Moguem Soubgui, Wilfred Steve Ndeme Mboussi, Loick Pradel 466 Kojom Foko, Elisee Libert Embolo Enyegue, Martin Luther Koanga Mogtomo. 467 Resources: Arlette Flore Moguem Soubgui, Martin Luther Koanga Mogtomo. 468 Project administration: Martin Luther Koanga Mogtomo. Software: Loick Pradel Kojom Foko. 469 470 Supervision: Martin Luther Koanga Mogtomo. 471 Validation: Loick Pradel Kojom Foko, Martin Luther Koanga Mogtomo. 472 Writing - original draft: Arlette Flore Moguem Soubgui, Loick Pradel Kojom Foko. 473 Writing - review & editing: Loick Pradel Kojom Foko, Martin Luther Koanga Mogtomo. Data availability statement 474 475 All data are within the manuscript and supporting files, and relevant data underlying the 476 results presented in the study has been filed in the Dryad repository and available from 477 https://doi.org/10.5061/dryad.1vhhmgr00. **Funding** 478 479 The author(s) received no specific funding for this work.

## **Competing interests**

481 The authors have declared that no competing interests exist.

## References

480

482

500

483	1.	Kojom LP, Singh V. A review on emerging infectious diseases prioritized under the
484		2018 WHO Research and Development Blueprint: Lessons from the Indian context.
485		Vector Borne Zoonotic Dis. 2021;21(3):149–59.
486	2.	Gautret P, Million M, Jarrot PA, Camoin-Jau L, Colson P, Fenollar F, et al. Natural
487		history of COVID-19 and therapeutic options. Expert Rev Clin Immunol.
488		2020;16(12):1159–84. Available from:
489		https://doi.org/10.1080/1744666X.2021.1847640
490	3.	Arevalo-Rodriguez I, Buitrago-Garcia D, Simancas-Racines D, Zambrano-Achig P,
491		Campo R Del, Ciapponi A, et al. False-negative results of initial RT-PCR assays for
492		COVID-19: A systematic review. PLoS One. 2020;15(12):e0242958.
493	4.	Saeed AY, Assafi MS, Othman HE, Shukri HM. Prevalence of SARS -CoV-2 IgG/IgM
494		antibodies among patients in Zakho City, Kurdistan, Iraq. J Infect Dev Ctries.
495		2022;16(7):1126–30.
496	5.	Mallano A, Ascione A, Flego M. Antibody response against SARS-CoV-2 infection:
497		Implications for diagnosis, treatment and vaccine development. Int Rev Immunol.
498		2022;41(4):393–413. Available from:
499		https://doi.org/10.1080/08830185.2021.1929205

Zhou W, Xu X, Chang Z, Wang H, Zhong X, Tong X, et al. The dynamic changes of serum


501 IgM and IgG against SARS-CoV-2 in patients with COVID-19. J Med Virol. 2021;93(2):924-33. 502 7. Kojom Foko LP, Nolla NP, Nyabeyeu Nyabeyeu H, Lehman LG. Prevalence, patterns, 503 and determinants of malaria and malnutrition in Douala, Cameroon: A cross-504 sectional community-based study. Biomed Res Int. 2021;2021:5553344. 505 8. Bobrovitz N, Arora RK, Cao C, Boucher E, Liu M, Donnici C, et al. Global seroprevalence 506 507 of SARS-CoV-2 antibodies: A systematic review and metaanalysis. PLoS One. 2021;16:e0252617. Available from: http://dx.doi.org/10.1371/journal.pone.0252617 508 9. Lang TA, Altman DG. Basic statistical reporting for articles published in Biomedical 509 510 Journals: The "Statistical analyses and methods in the published literature" or the SAMPL guidelines. Int J Nurs Stud. 2015;52(1):5–9. Available from: 511 http://dx.doi.org/10.1016/j.ijnurstu.2014.09.006 512 Aguilera X, González C, Apablaza M, Rubilar P, Icaza G, Ramírez-Santana M, et al. 513 10. 514 Immunization and SARS-CoV-2 antibody seroprevalence in a country with high vaccination coverage: Lessons from Chile. Vaccines. 2022;10(7):1002. 515 Poustchi H, Darvishian M, Mohammadi Z, Shayanrad A, Delavari A, Bahadorimonfared 516 11. A, et al. SARS-CoV-2 antibody seroprevalence in the general population and high-risk 517 518 occupational groups across 18 cities in Iran: a population-based cross-sectional study 519 Hossein. Lancet Infect Dis. 2021;21:473–81. 520 12. Arnaldo P, Mabunda N, Young PW, Tran T, Sitoe N, Chelene I, et al. Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic 521 study in three cities, July-August 2020. Clin Infect Dis. 2022;75(S2):S285–93. 522

523 13. Bahlawan O, Badra R, Semaan H, Fayad N, Kamel MN, El Taweel AN, et al. Prevalence and determinants of SARS-CoV-2 neutralizing antibodies in Lebanon. Arch Virol. 524 2022;167(7):1509–19. Available from: https://doi.org/10.1007/s00705-022-05470-2 525 14. Clarke KEN, Jones JM, Deng Y, Nycz E, Lee A, Iachan R, et al. Seroprevalence of 526 infection-induced SARS-CoV-2 antibodies-United States, September 2021-February 527 2022. Morb Mortal Wkly Rep. 2022;71(17):606–8. Available from: 528 529 https://www.medrxiv.org/content/10.1101/2022.04.18.22271936v1?rss Goss CW, Maricque BB, Anwuri V V, Cohen RE, Donaldson K, Johnson KJ, et al. SARS-530 15. CoV-2 active infection prevalence and seroprevalence in the adult population of St. 531 Louis County. Ann Epidemiol. 2022;71:31-7. 532 Johannesen CK, Martin GS, Lendorf ME, Garred P, Fyfe A, Paton RS, et al. Prevalence 533 16. and duration of anti-SARS-CoV-2 antibodies in healthcare workers. Dan Med J. 534 2022;69(5):A11210843. 535 536 17. Moreno S, Miró Q, Soler A, Gallego M, Homs M, Garcia MJ. Prevalence of SARS-CoV-2 antibodies and risk factors in the pandemic epicentre of Catalonia. Sci Rep. 537 2022;12(1):9169. Available from: https://doi.org/10.1038/s41598-022-13290-2 538 539 18. Mori Y, Tanaka M, Kozai H, Hotta K, Aoyama Y, Shigeno Y, et al. Prevalence of SARS-540 CoV-2 antibodies among university athletic club members: A cross-sectional survey. Drug Discov Ther. 2022;16(4):185-90. 541 542 19. Prguda-Mujic J, Hasanic O, Besic L, Asic A, Halilovic S, Cesic AK, et al. Antibody seroprevalence against SARS-CoV-2 within the Canton of Sarajevo, Bosnia and 543 Herzegovina-One year later. PLoS One. 2022;17(3):e0265431. Available from: 544

545 http://dx.doi.org/10.1371/journal.pone.0265431 546 20. Vena A, Berruti M, Adessi A, Blumetti P, Brignole M, Colognato R, et al. Prevalence of antibodies to SARS-CoV-2 in Italian adults and associated risk factors. J Clin Med. 547 2020;9(9):2780. 548 Żółtowska B, Barańska I, Jachowicz E, Sydor W, Maziarz B, Mydel K, et al. The 549 21. seroprevalence of SARS-CoV-2 antibodies among healthcare workers in university 550 551 hospital in Krakow before the era of vaccination. Int J Environ Res Public Health. 552 2022;19(7):4044. 22. Zuñiga M, Lagomarcino AJ, Muñoz S, Peña A, Andrea M, O'Ryan ML. A cross sectional 553 study found differential risks for COVID-19 seropositivity amongst health care 554 professionals in Chile. J Clin Epidemiol. 2022;144:72-83. 555 23. Javed W, Abidi SHB, Bagar J Bin. Seroprevalence and characteristics of Coronavirus 556 Disease (COVID-19) in workers with non-specific disease symptoms. BMC Infect Dis. 557 558 2022;22:481. Available from: https://doi.org/10.1186/s12879-022-07461-9 559 24. Arabkhazaeli A, Maghsudlu M, Mohammadi S, Eshghi P. Positive anti-SARS-CoV-2 560 rapid serological test results among asymptomatic blood donors. Transfus Clin Biol. 2022;29(1):24-30. 561 562 25. Bjorkander S, Du Ll, Zuo F, Ekstrom S, Wang Y, Wan H, et al. SARS-CoV-2-specific Band T-cell immunity in a population-based study of young Swedish adults. J Allergy 563 Clin Immunol. 2022;149(1):65-75. 564 26. Ferreira NB, Pereira H, Pereira AM, Azevedo LF, Santos M, Maranhão P, et al. 565 Seroprevalence of SARS-CoV-2 and assessement of epidemiological determinants in 566

567 Portugese municipal workers. Int J Occup Med Environ Health. 2022;35(3):297–307. 568 27. Martínez CA, Pastor JCS, Sánchez IMM, Giménez AN, de Antón MG, Chacón PA. Prevalence of SARS-CoV-2 infection during the first wave of the pandemic among 569 health and non-health personnel of the General Hospital of Segovia, Castilla y León. 570 Rev Esp Quimioter. 2022;35(2):157-64. 571 28. Aissatou A, Fokam J, Semengue ENJ, Takou D, Ka'e AC, Ambe CC, et al. Pre-existing 572 573 immunity to SARS-CoV-2 before the COVID-19 pandemic era in Cameroon: A 574 comparative analysis according to HIV-status. Front Immunol. 2023;14:1155855. 29. Nwosu K, Fokam J, Wanda F, Mama L, Orel E, Ray N, et al. SARS-CoV-2 antibody 575 seroprevalence and associated risk factors in an urban district in Cameroon. Nat 576 Commun. 2021;12:5851. 577 Nguwoh PS, Mboringong AB, Fokam J, Ngounouh Taheu C, Halilou I, Djieudeu Nouwe 578 30. SH, et al. Seroprevalence of SARS-CoV-2 (COVID-19) among health care workers in 579 580 three health facilities of Yaounde, Center Region of Cameroon. Eur J Med Health Sci. 2021;3(6):89-94. 581 Fai KN, Corine TM, Bebell LM, Mboringong AB, Nguimbis EBPT, Nsaibirni R, et al. 582 31. Serologic response to SARS-CoV-2 in an African population. Sci African. 583 2021;12:e00802. Available from: https://doi.org/10.1016/j.sciaf.2021.e00802 584 32. Ndongo Ateba F, Guichet E, Mimbé ED, Ndié J, Pelloquin R, Varloteaux M, et al. Rapid 585 increase of community SARS-CoV-2 seroprevalence during second wave of COVID-19, 586 Yaoundé, Cameroon. Emerg Infect Dis. 2022;28(6):1233-6. 587 Mansuy JM, Kenfack M, Burel S, Bidzogo Lebobo M, Ekae C, Berry A, et al. High SARS-588 33.

589 CoV-2 IgG seroprevalence among pregnant Cameroun women 14 months after the beginning of the pandemic. Public Health. 2022;S0033-3506(22)00260-8. 590 34. Deutou Wondeu AL, Talom BM, Linardos G, Ngoumo BT, Bello A, Soufo AMN, et al. 591 The COVID-19 wave was already here: High seroprevalence of SARS-CoV-2 antibodies 592 among staff and students in a Cameroon University. J Public Health Africa. 593 2023;14(1):2242. 594 595 35. Sandie AB, Ngo Sack F, Medi Sike CI, Mendimi Nkodo J, Ngegni H, Ateba Mimfoumou HG, et al. Spread of SARS-CoV-2 infection in adult populations in Cameroon: A 596 597 repeated cross-sectional study among blood donors in the cities of Yaoundé and Douala. J Epidemiol Glob Health. 2023;13(2):266–78. Available from: 598 599 https://doi.org/10.1007/s44197-023-00102-7 600 36. Diallo MSK, Amougou-Atsama M, Ayouba A, Kpamou C, Mimbe Taze ED, Thaurignac G, 601 et al. Large diffusion of severe acute respiratory syndrome coronavirus 2 after the 602 successive epidemiological waves, including Omicron, in Guinea and Cameroon: Implications for Vaccine Strategies. Open Forum Infect Dis. 2023;10(5):ofad216. 603 Available from: https://doi.org/10.1093/ofid/ofad216 604 37. Mksoud M, Ittermann T, Holtfreter B, Söhnel A, Söhnel C, Welk A, et al. Prevalence of 605 SARS-CoV-2 IgG antibodies among dental teams in Germany. Clin Oral Investig 606 [Internet]. 2022;26(5):3965-74. Available from: https://doi.org/10.1007/s00784-021-607 608 04363-z 609 38. Chang L, Hou W, Zhao L, Zhang Y, Wang Y, Wu L, et al. The prevalence of antibodies to SARS-CoV-2 among blood donors in China. Nat Commun. 2021;12:1383. 610



Immunol. 2021;151:49-97.

- 46. Tian Y, Carpp LN, Miller HE, Zager M, Newell EW, Gottardo R. Singular insights into the immunology of SARS-CoV-2 infection. Nat Biotechnol. 2022;40(1):30–41.
- DiPiazza AT, Graham BS, Ruckwardt TJ. T cell immunity to SARS-CoV-2 following
   natural infection and vaccination. Biochem Biophys Res Commun. 2021;538:211–7.
- 638 48. Forchette L, Sebastian W, Liu T. A comprehensive review of COVID-19 virology, 639 vaccines, variants, and therapeutics. Curr Med Sci. 2021;41(6):1037–51.
- 640 49. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell.
- 641 2021;184:861–80.
- 642 50. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China Chuan. Clin Infect Dis. 2020;71(15):762–8.
- Singh M, Barrera Adame O, Nickas M, Robison J, Khatchadourian C, Venketaraman V.
   Type 2 diabetes contributes to altered adaptive immune responses and vascular
- inflammation in patients with SARS-CoV-2 infection. Front Immunol. 2022;13:833355.
- 647 52. Moguem Soubgui AF, Kojom Foko LP, Embolo Enyegue EL, Ndeme Mboussi WS, Mbebi 648 Enone JP, Ntatou Lemouchele I, et al. Confounding role of comorbidities and COVID—
- 19 vaccination uptake in clinical utility of hematological biomarkers in Cameroonian
- patients infected with SARS–CoV–2. IJID. 2023;Ahead of Print.
- 651 53. Parthasarathi A, Basavaraja CK, Arunachala S, Chandran S, Venkataraman H, Satheesh
  652 A, et al. Comorbidities influence the predictive power of hematological markers for
  653 mortality in hospitalized COVID-19 patients. Adv Respir Med. 2022;90(1):49–59.

654 54. Centers for Disease Control and Prevention. People who are at higher risk for severe illness | CDC. Centers Dis Control Prev. 2020;68:703–10. Available from: 655 https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-656 higher-risk.html 657 Moguem Soubgui AF, Embolo Enyegue EL, Kojom Foko LP, Ndeme Mboussi WS, 658 55. Deutou Hogoue G, Mbougang SP, et al. Epidemiological situation of SARS-CoV-2 659 660 infection in Douala, the most populated and highly heterogeneous town of Cameroon: a post-vaccination update. Acta Trop. 2023;241:106864. Available from: 661 https://doi.org/10.1016/j.actatropica.2023.106864 662 Ebongue MSN, Lemogoum D, Endale-Mangamba LM, Barche B, Eyoum C, Simo Yomi 56. 663 664 SH, et al. Factors predicting in-hospital all-cause mortality in COVID 19 patients at the Laquintinie Hospital Douala, Cameroon. Travel Med Infect Dis. 2022;47:102292. 665 666 Available from: https://doi.org/10.1016/j.tmaid.2022 667 57. Mercado-Reyes MM, Daza M, Pacheco A, Meneses-Gil MX, Galindo M, Catama J, et al. Seroprevalence of SARS-CoV-2 antibodies in children and adolescents: Results from a 668 669 population-based survey in 10 Colombian cities. Glob Pediatr Heal. 2022;9:1–16. 670 58. Talaei M, Faustini S, Holt H, Jolliffe DA, Vivaldi G, Greenig M, et al. Determinants of 671 pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal study (COVIDENCE UK). BMC Med. 2022;20:87. Available from: 672 https://doi.org/10.1186/s12916-022-02286-4 673 674 59. Rodríguez MF, Porras-Villamil JF, Martin L V., Rivera JE, Mantilla YC, Olivera MJ. Seroprevalence of IgM and IgG anti-SARS-COV-2 and associated factors among 675 agricultural workers in Colombia. New Microbes New Infect. 2022;48:101026. 676

Available from: https://doi.org/10.1016/j.nmni.2022.101026 677 Colson P, Delerce J, Burel E, Dahan J, Jouffret A, Fenollar F, et al. Emergence in 678 60. southern France of a new SARS-CoV-2 variant harbouring both N501Y and E484K 679 substitutions in the spike protein. Arch Virol. 2022;167(4):1185–90. Available from: 680 https://doi.org/10.1007/s00705-022-05385-y 681 61. Chouikha A, Lagare A, Ghedira K, Diallo A, Njouom R, Sankhe S, et al. SARS-CoV-2 682 683 lineage A.27: New data from African countries and dynamics in the context of the 684 COVID-19 pandemic. Viruses. 2022;14(5):1007. 62. Njouom R, Sadeuh-mba SA, Tchatchueng J, Dia N, Tagnouokam Ngoupo PA, Boum Y, 685 686 et al. Coding-complete genome sequence and phylogenetic relatedness of a SARS-CoV-2 strain detected in March 2020 in Cameroon. Microbiol Resour Announc. 687 2020;3:e00093-21. 688 689 690 691 692 693 694 695 696

Page **38** of **38** 

**Supporting information** 

697

698	S1 Fig. Ethical clearance of the study.
699	S2 Fig. Testing SARS-CoV-2 immune response parameters (IgM, IgG, CD4+, IFN-γ and IL-6)
700	and age for Gaussian distribution.
701	S3 Table. SARS-CoV-2 seroprevalence profile by health facilities.
702	S4 Table. SARS-CoV-2 seroprevalence profile by clinical symptoms.
703	S5 Table. Clinical value of symptoms for prognostic of IgG seropositivity.
704	S6 Table. Association between immune response and patients' characteristics among
705	COVID-19 unvaccinated patients.
706	S7 Table. Details of multivariate logistic regression analysis of the presence of anti-SARS-
707	CoV-2 IgM or IgG antibodies.




Fig 1





Fig 2






Fig 3

Fig 4




Fig 5




Fig 6